Tsai-Fan Yu

Last updated • 4 min readFrom Wikipedia, The Free Encyclopedia
Tsai-Fan Yu
Tsai-Fan Yu.jpeg
Born1911 (1911)
Shanghai, China
Died (aged 95)
Alma mater
Known forResearch on gout
Scientific career
FieldsMedicine
Institutions

Tsai-Fan Yu (Chinese :郁采蘩; pinyin :Yù Cǎifán; Wade–Giles :Yü Ts'ai-fan, 1911 – March 2, 2007) was a Chinese-American physician, researcher, and the first woman to be appointed as a full professor at Mount Sinai School of Medicine. She helped to develop an explanation for the cause of gout and experimented with early drugs to treat the disease which are still in use today.

Contents

Early life and education

Yu was born in Shanghai, China in 1911. At age 13, her mother died and her father worked three jobs to help support her educational ambitions. As a sophomore at Ginling College in China, Yu was admitted into Peking Union Medical College on full scholarship and received her medical degree with highest honors in 1939. In the same year, Yu became the Chief Resident in Internal Medicine at Peking Union Medical College. [1] [2] [3]

Career and research

While in China, Yu researched the various diseases found in citrus fruits and beans. Yu came to New York in 1947 and became a U.S. citizen in 1950. She taught at Columbia University College of Physicians and Surgeons until joining the staff faculty at Mount Sinai Medical Center in 1957 where she would spend the rest of her career. In 1973, Yu became the first female to be appointed as a full professor at Mount Sinai Hospital, one of the oldest and largest teaching hospitals in The United States. [1] [2]

Causes of Gout

Yu conducted extensive research in which was continuously funded by the National Institutes of Health for 26 years. She began studying renal function in various diseases such as Wilson's disease before focusing her research on gout at Mount Sinai. Yu helped to establish an understanding of the metabolic relationship between elevated levels of uric acid and the pain experienced by gout patients. [1] [2] She aimed to classify and determine the differences the various forms of gout, such as acute gouty arthritis and chronic tophaceuous gout. [4] Yu also studied the effect that other medication conditions have on the presentation of gout. She found that about half of the patients with gout have other associated medication conditions, including hypertension, proteinuria, diabetes, and hyperlipidemia. [5]

Treatment of Gout

Beginning in the 1950s, Yu developed medicines that have been proven to be successful for treating gout. In addition, Yu and her colleague Alexander B. Gutman helped to establish a groundbreaking clinic at Mount Sinai for the treatment of gout, one of the first gout clinics in the United States at Mount Sinai. Yu studied probenecid, a uricosuric drug which causes the removal of excess uric acid by being excreted with urine. She later conducted a five-year study that was published in 1961 in which she discovered colchicine, an anti-inflammatory drug that prevents recurring attacks of acute gout. [1] [2] In 1953, Yu conducted research on phenylbutazone as a treatment for various arthritic disorders, one being acute gouty arthritis. She and colleagues found that phenylbutazone injections lead to significantly higher urate clearance and more efficient excretion, making it successful in treating acute gout. [6] In the 1960s, Yu further developed studies of gout’s mechanisms and soon discovered allopurinol, a drug that helps to prevent the formation of uric acid and is used in treating gout and kidney stones. [1] In 1980, she studied carprofen and its effect on urinary excretion. She found it was effective for treating acute gouty arthritis and recommended further trials. [5] While at Mount Sinai Hospital, Yu helped to establish one of the first systemized laboratory tests for diagnosing rheumatoid arthritis. [1]

In 1972, Yu co-authored and published Gout and Uric Acid Metabolism and in 1982, she published the book called The Kidney in Gout and Hyperuricemia . [7]

Awards and honors

At age 81, Yu retired as the first female professor at Mount Sinai Hospital with professor Emeritus status in 1992. She was awarded the Distinguished Career Achievement Award from the Mount Sinai Medical Center. She was also awarded the Master Award from the American Association of Rheumatology for her work in diagnosing rheumatoid arthritis. In 2004, The Tsai-Fan Yu Foundation was established as a philanthropic nonprofit corporation. [8] [9] Over the course of her career, she worked with over 4000 gout patients at one of the largest gout-focused practices. [2] She also published 220 scientific journal articles and is known for her ability to translate lab research into an effective treatment for patients. [2] She is aunt to Hua Eleanor Yu, a professor in tumor immunotherapy and Humboldt Research Award recipient. Yu died at age 95 in March 2007 due to respiratory complications at Mount Sinai Medical Center in Manhattan. [1] [2]

See also

Related Research Articles

<span class="mw-page-title-main">Uric acid</span> Organic compound

Uric acid is a heterocyclic compound of carbon, nitrogen, oxygen, and hydrogen with the formula C5H4N4O3. It forms ions and salts known as urates and acid urates, such as ammonium acid urate. Uric acid is a product of the metabolic breakdown of purine nucleotides, and it is a normal component of urine. High blood concentrations of uric acid can lead to gout and are associated with other medical conditions, including diabetes and the formation of ammonium acid urate kidney stones.

<span class="mw-page-title-main">Gout</span> Form of arthritis causing swollen joints

Gout is a form of inflammatory arthritis characterized by recurrent attacks of pain in a red, tender, hot, and swollen joint, caused by the deposition of needle-like crystals of uric acid known as monosodium urate crystals. Pain typically comes on rapidly, reaching maximal intensity in less than 12 hours. The joint at the base of the big toe is affected (Podagra) in about half of cases. It may also result in tophi, kidney stones, or kidney damage.

<span class="mw-page-title-main">Allopurinol</span> Medication

Allopurinol is a medication used to decrease high blood uric acid levels. It is specifically used to prevent gout, prevent specific types of kidney stones and for the high uric acid levels that can occur with chemotherapy. It is taken orally or intravenously.

<span class="mw-page-title-main">Hyperuricemia</span> Medical condition

Hyperuricaemia or hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid, uric acid exists largely as urate, the ion form. Serum uric acid concentrations greater than 6 mg/dL for females, 7 mg/dL for men, and 5.5 mg/dL for youth are defined as hyperuricemia. The amount of urate in the body depends on the balance between the amount of purines eaten in food, the amount of urate synthesised within the body, and the amount of urate that is excreted in urine or through the gastrointestinal tract. Hyperuricemia may be the result of increased production of uric acid, decreased excretion of uric acid, or both increased production and reduced excretion.

Tumor lysis syndrome (TLS) is a group of metabolic abnormalities that can occur as a complication from the treatment of cancer, where large amounts of tumor cells are killed off (lysed) from the treatment, releasing their contents into the bloodstream. This occurs most commonly after the treatment of lymphomas and leukemias and in particular when treating non-Hodgkin lymphoma, acute myeloid leukemia, and acute lymphoblastic leukemia. This is a potentially fatal complication and patients at increased risk for TLS should be closely monitored while receiving chemotherapy and should receive preventive measures and treatments as necessary. TLS can also occur on its own although this is less common.

<span class="mw-page-title-main">Phenylbutazone</span> Nonsteroidal anti-inflammatory drug (NSAID)

Phenylbutazone, often referred to as "bute", is a nonsteroidal anti-inflammatory drug (NSAID) for the short-term treatment of pain and fever in animals.

<span class="mw-page-title-main">Urate oxidase</span> Pseudogene in the species Homo sapiens

The enzyme urate oxidase (UO), uricase or factor-independent urate hydroxylase, absent in humans, catalyzes the oxidation of uric acid to 5-hydroxyisourate:

<span class="mw-page-title-main">Lesch–Nyhan syndrome</span> Rare genetic disorder

Lesch–Nyhan syndrome (LNS) is a rare inherited disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This deficiency occurs due to mutations in the HPRT1 gene located on the X chromosome. LNS affects about 1 in 380,000 live births. The disorder was first recognized and clinically characterized by American medical student Michael Lesch and his mentor, pediatrician William Nyhan, at Johns Hopkins.

<span class="mw-page-title-main">Tophus</span> Medical condition

A tophus is a deposit of monosodium urate crystals, in people with longstanding high levels of uric acid (urate) in the blood, a condition known as hyperuricemia. Tophi are pathognomonic for the disease gout. Most people with tophi have had previous attacks of acute arthritis, eventually leading to the formation of tophi. Chronic tophaceous gout is known as Harrison Syndrome.

<span class="mw-page-title-main">Rasburicase</span> Pharmaceutical drug

Rasburicase is a medication that helps to clear uric acid from the blood. It is a recombinant version of urate oxidase, an enzyme that metabolizes uric acid to allantoin. Urate oxidase is known to be present in many mammals but does not naturally occur in humans. Rasburicase is produced by a genetically modified Saccharomyces cerevisiae strain. The complementary DNA (cDNA) coding for rasburicase was cloned from a strain of Aspergillus flavus.

<span class="mw-page-title-main">Monoarthritis</span> Medical condition

Monoarthritis, or monoarticular arthritis, is inflammation (arthritis) of one joint at a time. It is usually caused by trauma, infection, or crystalline arthritis.

<span class="mw-page-title-main">Carprofen</span> Non-steroidal anti-inflammatory drug

Carprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the carbazole and propionic acid class that was previously for use in humans and animals but is now only available to veterinarians for prescribing as a supportive treatment for various conditions in animals. Carprofen reduces inflammation by inhibition of COX-1 and COX-2; its specificity for COX-2 varies from species to species. Marketed under many brand names worldwide, carprofen is used as a treatment for inflammation and pain, including joint pain and postoperative pain.

Uricosuric medications (drugs) are substances that increase the excretion of uric acid in the urine, thus reducing the concentration of uric acid in blood plasma. In general, this effect is achieved by action on the proximal tubule of the kidney. Drugs that reduce blood uric acid are not all uricosurics; blood uric acid can be reduced by other mechanisms.

<span class="mw-page-title-main">Hypouricemia</span> Medical condition

Hypouricemia or hypouricaemia is a level of uric acid in blood serum that is below normal. In humans, the normal range of this blood component has a lower threshold set variously in the range of 2 mg/dL to 4 mg/dL, while the upper threshold is 530 μmol/L (6 mg/dL) for women and 619 μmol/L (7 mg/dL) for men. Hypouricemia usually is benign and sometimes is a sign of a medical condition.

Acute uric acid nephropathy is a rapidly worsening (decreasing) kidney function that is caused by high levels of uric acid in the urine (hyperuricosuria).

<span class="mw-page-title-main">SLC22A12</span> Mammalian protein found in Homo sapiens

Solute carrier family 22, member 12, also known as SLC22A12 and URAT1, is a protein which in humans is encoded by the SLC22A12 gene.

<span class="mw-page-title-main">Oxipurinol</span> Chemical compound

Oxipurinol is an inhibitor of xanthine oxidase. It is an active metabolite of allopurinol and it is cleared renally. In cases of renal disease, this metabolite will accumulate to toxic levels. By inhibiting xanthine oxidase, it reduces uric acid production. High serum uric acid levels may result in gout, kidney stones, and other medical conditions.

Sān miào wán is a traditional Chinese medicine consisting of three components:

Nicola Dalbeth is a New Zealand academic rheumatologist whose research focuses on understanding the impact and mechanisms of gout. She supports clinical and laboratory research programmes and holds dual appointments as a full professor at the University of Auckland and as a consultant for the Auckland District Health Board.

<span class="mw-page-title-main">Gout suppressants</span> Drugs to control and prevent gout attacks

Gout suppressants are agents which control and prevent gout attacks after the first episode. They can be generally classified into two groups by their purpose: drugs used for induction therapy and that for maintenance therapy.

References

  1. 1 2 3 4 5 6 7 "Dr. Tsai-fan Yu (1911 - 2007)". National Women's History Museum. Archived from the original on 2017-06-09. Retrieved 2019-04-28.
  2. 1 2 3 4 5 6 7 Pearce, Jeremy (March 12, 2007). "Tsai-Fan Yu, 95, Physician, Dies; Helped Alleviate Gout". The New York Times. Retrieved 23 March 2014.
  3. "Tsai- Fan Yu Obituary". New York Times. Retrieved 24 March 2014.
  4. Gutman, Alexander B.; Yü, T. F. (1952-12-01). "Current principles of management in gout". The American Journal of Medicine. 13 (6): 744–759. doi:10.1016/0002-9343(52)90374-4. ISSN   0002-9343. PMID   13016572.
  5. 1 2 Yü, Ts'Ai-Fan; Perel, James (1980-05-06). "Pharmacokinetic and Clinical Studies of Carprofen in Gout". The Journal of Clinical Pharmacology. 20 (5–6): 347–351. doi:10.1177/009127008002000507. PMID   7400372. S2CID   23692328.
  6. Yü, Tsai Fan; Sirota, Jonas H.; Gutman, Alexander B. (1953-11-01). "EFFECT OF PHENYLBUTAZONE (3,5 DIOXO-1,2-DIPHENYL-4-n-BUTYLPYRAZOLIDINE) ON RENAL CLEARANCE OF URATE AND OTHER DISCRETE RENAL FUNCTIONS IN GOUTY SUBJECTS 1". Journal of Clinical Investigation. 32 (11): 1121–1132. doi: 10.1172/jci102836 . ISSN   0021-9738. PMC   438451 . PMID   13108975.
  7. Talbott, John; Tsai-Fan (1976). Gout and Uric Acid Metabolism. New York: Stratton Intercontinental Medical Book Corporation.
  8. "Nonprofit Explorer – Tsai-Fan Yu Foundation". ProPublica. 9 May 2013. Retrieved 2015-04-20.
  9. "Tsai- Fan Yu Foundation". NonProfotFacts. Retrieved 24 March 2014.